Resuscitation and Prevention of Ischemia-Induced Dysfunction (RAPIID) - TA1/TA2
Overview
Buyer
Place of Performance
NAICS
PSC
Set Aside
Original Source
Timeline
Qualification Details
Fit reasons
- NAICS alignment with historical contract wins in similar service areas.
- Scope strongly matches core technical capabilities and delivery model.
Risks
- Past performance thresholds may require one additional teaming partner.
- Potential clarification needed on staffing minimums before bid/no-bid.
Next steps
Validate eligibility requirements, assign capture owner, and schedule partner outreach to confirm teaming strategy before submission planning.
Quick Summary
The Defense Advanced Research Projects Agency (DARPA), specifically its Biological Technologies Office (BTO), has issued a Solicitation for the Resuscitation and Prevention of Ischemia-Induced Dysfunction (RAPIID) program. This initiative seeks proposals for Phase 1 ONLY of Task Area (TA)-1 and/or TA-2 to develop a transformative, end-to-end blood analog system (BAS) for far-forward trauma care. The goal is to create a fieldable, usable, and scalable capability equivalent or superior to stored whole blood, eliminating reliance on cold chain and donor logistics.
Scope of Work
The RAPIID program aims to develop a blood analog system (BAS) comprising sequentially administered blood analog components, integrated with ruggedized delivery formats, point-of-care diagnostics, and clinical practice guidelines. Technologies are expected to advance to Technology Readiness Level (TRL) 7 for components and TRL 8 for devices/diagnostics.
- TA-1: Individual Blood Analog Components – Focuses on developing shelf-stable components such as oxygen carriers, platelet-derived products, or dried plasma. Proposals for oxygen carriers or platelet-like particles must also include a TA-2 detection technology.
- TA-2: Blood Analog System (BAS) Fielding Technologies – Concentrates on developing delivery formats and point-of-care diagnostics to support far-forward use, transfusion decisions, and analysis of blood analog effects.
Contract Details & Timeline
- Contract Type: Other Transaction (OT) for Prototype.
- Period of Performance: Phase 1 is 12 months. Phase 2 is an option for 24 months.
- Questions Due: June 3, 2026, 4:00 PM ET.
- Proposal Due: June 24, 2026, 4:00 PM ET.
- Published Date: May 27, 2026.
Eligibility & Evaluation
- Eligibility: Open to large and small businesses, nontraditional defense contractors, and research institutions. Federal Funded Research and Development Centers (FFRDCs), University Affiliated Research Centers (UARCs), and Government Entities are not eligible. Organizations awarded TA-1/TA-2 are not eligible for TA-3/TA-4 awards.
- Set-Aside: None specified.
- Evaluation Criteria: Proposals will be assessed based on Overall Scientific and Technical Merit, Potential Contribution and Relevance to DARPA Mission, and Cost and Schedule Realism.
Submission Requirements & Notes
Proposers must submit full proposals via DARPA’s Broad Agency Announcement Tool (BAAT). Mandatory attachments include a Technical and Management Proposal (Attachment A), Cost Proposal (Attachment B) using the DARPA Standard Cost Proposal Spreadsheet (Attachment C), a Task Description Document (Attachment E), and a Schedule of Milestones and Payments (Attachment F). Bidders must also understand and comply with the Controlled Unclassified Information (CUI) Guide (Attachment G) and review the Model Other Transaction for Prototype Agreement (Attachment D). Proposers must have a Unique Identity ID and be registered in SAM.gov.